3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes James Hury of TRISH, Serafina Lalany of HX, and Andrew Ramirez of Village Insights. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space health to virtual collaboration — recently making headlines in Houston innovation.

James Hury, deputy director and chief innovation officer of TRISH

James Hury joins the Houston Innovators Podcast to discuss the role of the Translational Research Institute for Space Health. Photo courtesy of TRISH

Only about 500 humans have made it to space, and that number is getting bigger thanks to commercial space travel.

"If you look at all the people who have gone into space, they've mostly been employees of nations — astronauts from different governments," says James Hury of the Translational Research Institute for Space Health on this week's episode of the Houston Innovators Podcast. "We're going to start to get people from all different ages and backgrounds."

Hury is the deputy director and chief innovation officer for Houston-based TRISH, and he's focused on identifying space tech and research ahead of the market that has the potential to impact human health in space. From devices that allow astronauts to perform remote health care on themselves to addressing behavioral health challenges, TRISH is supporting the future of space health. Click here to read more and stream the podcast.

Serafina Lalany, executive director of Houston Exponential

Serafina Lalany, vice president of operations at Houston Exponential

HX has its new permanent leader. Photo courtesy of Serafina Lalany

Houston's nonprofit focused on accelerating the growth of the local innovation ecosystem has named its new leader.

Serafina Lalany has been named Houston Exponential's executive director. She has been serving in the position as interim since July when Harvin Moore stepped down. Prior to that, she served as vice president of operations and chief of staff at HX.

"I'm proud to be leading an organization that is focused on elevating Houston's startup strengths on a global scale while helping to make the world of entrepreneurship more accessible, less opaque, and easier to navigate for founders," Lalany says in a news release. "My team and I will be building upon the great deal of momentum that has already been established in this effort, and I look forward to collaborating closely with members of our community and convening board in this next chapter of HX." Click here to read more.

Andrew Ramirez, CEO of Village Insights

Andrew Ramirez originally worked on a similar project 10 years ago. Photo via LinkedIn

Innovation thrives on collisions, but how do innovators connect without face-to-face connection? Andrew Ramirez and Mike Francis set out to design a virtual village to promote collisions and innovation, and their platform is arriving at an apt time.

"The world has changed," Ramirez says. "I feel like people are trying to find the right balance of the physical but also the productivity gain from being able to do things digitally."

Ramirez leads Village Insights as CEO and the new platform is expected to formally launch it's Open World platform next month. Click here to read more.

James Hury joins the Houston Innovators Podcast to discuss the role of the Translational Research Institute for Space Health. Photo courtesy of TRISH

Houston innovator talks space health and the future of the commercial sector

houston innovators podcast episode 102

Only about 500 humans have made it to space, which, from a research perspective, isn't a large data set. Yet as commercial space exploration continues and more people make it up into space, new opportunities for space health research are being made available.

The organization, which is housed out of Baylor College of Medicine and supported by NASA, has a major role to play in the future of space. The Federal Aviation Administration released new space travel regulations that require travelers to contribute something to society. One way to check that box is to collaborate with TRISH on its research.

"If you are willing to go and help participate in experimentation and research endeavors, then you are helping to gain knowledge for all of humankind," Hury says of future space travelers willing to pay tens of millions of dollars to go to space.

TRISH has stood up the first commercial spaceflight medical research program to work with commercial spaceflight crews to bring back crucial research to one database. Called EXPAND — Enhancing eXploration Platforms and Analog Definition — the new collaborative program is meant to address the challenges that humans face on space missions — early detection and treatment of medical conditions, protection from radiation, mental health, team dynamics, and more.

The human aspect of space exploration has always been at the core of Houston's space industry. And this isn't going to change as commercialization within the sector continues.

"I think we'll be Space City forever," Hury says on the show. "We have a whole lot of expertise here that can support this new economy."

He shares more on the future of space health and Houston's role in space exploration on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

If Houston wants to maintain its title as Space City, it needs to channel the innovation of its history as space exploration moves forward. Pexels

Houston can stay the Space City within medical and health innovation

Guest column

Space has captured the imagination of mankind since we first looked up at the night sky. We've reached out to touch the stars, and now endeavor to inhabit them.

Earlier this month, a prominent collection of experts on space health attended the first Space Health Innovation Conference co-hosted by the University of California, San Francisco, and Houston-based Translational Research Institute for Space Health.

As NASA eyes a return to the moon with the Artemis Program, attendees of the Space Health Innovation Conference advanced a national discussion of human space exploration by seeking to manage the many health risks associated with humans during space flight. The event included NASA leadership, innovative companies, commercial space vendors, as well as leaders from the space health and life sciences communities.

The conference's goal is to inform, inspire and invite participation in the exciting challenge of optimizing health and medical management in space environments.

With its headquarters in Houston, TRISH partnered with the Human Research Program at Johnson Space Center to source and seed the best emerging health technologies to support NASA's space exploration. TRISH is based out of the Center for Space Medicine at Baylor College of Medicine and is a consortium that includes the rich space pedigree of the Massachusetts Institute of Technology and the California Institute of Technology. The Space Health Innovation Conference is the result of a grant by TRISH to UCSF. TRISH has also hosted Space Health focused events at the MIT Media lab and at Caltech.

TRISH's main charge is finding disruptive health technologies and new scientists to fuel the US Space Program. TRISH explores emerging areas of science that support health and human performance in the harsh environment of microgravity and high radiation. TRISH funds novel research in artificial intelligence, omics, human computer interfaces, behavioral health and beyond. Projects all share one goal: predicting and protecting future Mars explorers. And NASA leadership encourages TRISH to take the risks that could mean huge leaps forward.

Innovation and risk tolerance are hallmarks of Houston and its rich history. From the city's humble origins, to Jesse Jones's national financial leadership, to the building of the Houston Ship Channel, and to the explosion of the energy industry, Houston has always dared to leap forward. President John F. Kennedy's iconic speech entitled "Address at Rice University on the Nation's Space Effort" declared the US ambition to embrace the new frontier of space and conquer the moon. Humble Oil donated the 1,620 acres for JSC to Rice University, who then sold the land to NASA for $20. (Humble Oil would later become Exxon Mobil.)

JSC housed flight control, space flight training, and the NASA Astronaut Corps. JSC gave Houston the nickname "Space City", which led to the naming of the local NBA team to be the Rockets and the local MLB team to be the Astros. JSC's support for the astronaut corps began with the Lunar Receiving Laboratory, which evaluated the Apollo astronauts upon return to Earth. And the Christopher C Kraft Mission Control facility has directed all crewed space flights since the early Gemini program. An American flag flies atop Mission Control at JSC every day that an American is in space. That flag has flown continuously since November 2, 2000.

Nearly two decades since Bill Shepherd first boarded the International Space Station, the conversation around supporting human health and performance in space continues. And Houston will continue to lead the way for all our sakes, in space and on terra firma.

------

James Hury is the deputy director and chief innovation officer at Houston-based Translational Research Institute for Space Health.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME